These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9481720)

  • 1. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium.
    Kooistra MP; Niemantsverdriet EC; van Es A; Mol-Beermann NM; Struyvenberg A; Marx JJ
    Nephrol Dial Transplant; 1998 Jan; 13(1):82-8. PubMed ID: 9481720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients.
    Kooistra MP; Marx JJ
    Nephrol Dial Transplant; 1998 Oct; 13(10):2578-82. PubMed ID: 9794563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
    Casati S; Castelnovo C; Campise M; Ponticelli C
    Nephrol Dial Transplant; 1990; 5(6):441-3. PubMed ID: 2122321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
    Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
    Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores.
    Hughes RT; Smith T; Hesp R; Hulme B; Dukes DC; Bending MB; Pearson J; Raja KB; Cotes PM; Pippard MJ
    Br J Haematol; 1992 Oct; 82(2):445-54. PubMed ID: 1419827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
    Tarng DC; Huang TP
    Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
    Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
    Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.
    Muirhead N; Hodsman AB; Hollomby DJ; Cordy PE
    Nephrol Dial Transplant; 1991; 6(5):342-5. PubMed ID: 1870750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
    Chang CH; Chang CC; Chiang SS
    Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
    Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
    Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal aluminium absorption: is it modulated by the iron-absorptive mechanism?
    Cannata JB; Suarez Suarez C; Cuesta V; Rodriguez Roza R; Allende MT; Herrera J; Perez Llanderal J
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():354-9. PubMed ID: 3991522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis.
    Alfurayh O; Sobh M; Barri Y; Qunibi W; Taher S
    Nephrol Dial Transplant; 1992; 7(9):939-43. PubMed ID: 1328942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of iron supply for erythropoietin therapy.
    Sunder-Plassmann G; Hörl WH
    Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy.
    Tarng DC; Huang TP; Chen TW
    Am J Nephrol; 1997; 17(2):158-64. PubMed ID: 9096447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of iron deficiency in erythropoietin sensitivity in dialysis patients with elevated C-reactive protein].
    Martone M; Zanchi R; Panzetta G
    G Ital Nefrol; 2003; 20(1):31-7. PubMed ID: 12647284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
    Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
    Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
    Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.